RESUMO
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that currently has no cure. Identifying biochemical changes associated with neurodegeneration prior to symptom onset, will provide insight into the biological mechanisms associated with neurodegenerative processes, that may also aid in identifying potential drug targets. The current study therefore investigated associations between plasma neurofilament light chain (NF-L), a marker of neurodegeneration, with plasma metabolites that are products of various cellular processes. Plasma NF-L, measured by ultrasensitive Single molecule array (Simoa) technology (Quanterix) and plasma metabolites, measured by mass-spectrometry (AbsoluteIDQ® p400HR kit, BIOCRATES), were assessed in the Kerr Anglican Retirement Village Initiative in Ageing Health (KARVIAH) cohort comprising 100 cognitively normal older adults. Metabolites belonging to biogenic amine (creatinine, symmetric dimethylarginine, asymmetric dimethylarginine; ADMA, kynurenine, trans-4-hydroxyproline), amino acid (citrulline, proline, arginine, asparagine, phenylalanine, threonine) and acylcarnitine classes were observed to have positive correlations with plasma NF-L, suggesting a link between neurodegeneration and biological pathways associated with neurotransmitter regulation, nitric oxide homoeostasis, inflammation and mitochondrial function. Additionally, after stratifying participants based on low/high brain amyloid-ß load (Aß ±) assessed by positron emission tomography, while creatinine, SDMA and citrulline correlated with NF-L in both Aß- and Aß+ groups, ADMA, proline, arginine, asparagine, phenylalanine and acylcarnitine species correlated with NF-L only in the Aß+ group after adjusting for confounding variables, suggesting that the association of these metabolites with neurodegeneration may be relevant to AD-related neuropathology. Metabolites identified to be associated with plasma NF-L may have the potential to serve as prognostic markers for neurodegenerative diseases, however, further studies are required to validate the current findings in an independent cohort, both cross-sectionally and longitudinally.
Assuntos
Doenças Neurodegenerativas/sangue , Idoso , Idoso de 80 Anos ou mais , Peptídeos beta-Amiloides/análise , Aminas Biogênicas/metabolismo , Biomarcadores/análise , Cognição , Estudos de Coortes , Encefalite/metabolismo , Feminino , Humanos , Masculino , Espectrometria de Massas/métodos , Mitocôndrias/metabolismo , Doenças Neurodegenerativas/diagnóstico , Doenças Neurodegenerativas/psicologia , Proteínas de Neurofilamentos/análise , Neurotransmissores/metabolismo , Óxido Nítrico/metabolismo , Tomografia por Emissão de Pósitrons , PrognósticoRESUMO
Microplastics (MPs) can pose ecological risk to the environment and have the potential to negatively affect human health, raising serious public concerns. It is recognized that MPs could act as a vector for various environmental pollutants including heavy metals and potentially influencing their mobility, fate, and bioavailabilty in the environment. However, knowledge on the mechanisms underpinning the interaction processes between MPs and heavy metals is far from clear. This review discusses the effects of MPs on the adsorption/desorption, speciation and bioavailability, and toxicity of various heavy metals. The present review also systematically identifies the environmental factors (e.g., pH, ionic strength, and organic matters) that could affect their interaction processes. This work aims to establish a meaningful perspective for a comprehensive understanding of the indirect ecological risks of MPs as vectors for contaminants. The work also provides a reference for the development of better regulatory strategies in mitigating the negative effects caused by the co-existence of MPs and heavy metals.
Assuntos
Metais Pesados , Poluentes Químicos da Água , Disponibilidade Biológica , Humanos , Metais Pesados/toxicidade , Microplásticos , Plásticos/toxicidade , Poluentes Químicos da Água/análise , Poluentes Químicos da Água/toxicidadeRESUMO
BACKGROUND: Blood markers indicative of neurodegeneration (neurofilament light chain; NFL), Alzheimer's disease amyloid pathology (amyloid-ß; Aß), and neuroinflammation (kynurenine pathway; KP metabolites) have been investigated independently in neurodegenerative diseases. However, the association of these markers of neurodegeneration and AD pathology with neuroinflammation has not been investigated previously. Therefore, the current study examined whether NFL and Aß correlate with KP metabolites in elderly individuals to provide insight on the association between blood indicators of neurodegeneration and neuroinflammation. METHODS: Correlations between KP metabolites, measured using liquid chromatography and gas chromatography coupled with mass spectrometry, and plasma NFL and Aß concentrations, measured using single molecule array (Simoa) assays, were investigated in elderly individuals aged 65-90 years, with normal global cognition (Mini-Mental State Examination Score ≥ 26) from the Kerr Anglican Retirement Village Initiative in Ageing Health cohort. RESULTS: A positive correlation between NFL and the kynurenine to tryptophan ratio (K/T) reflecting indoleamine 2,3-dioxygenase activity was observed (r = .451, p < .0001). Positive correlations were also observed between NFL and kynurenine (r = .364, p < .0005), kynurenic acid (r = .384, p < .0001), 3-hydroxykynurenine (r = .246, p = .014), anthranilic acid (r = .311, p = .002), and quinolinic acid (r = .296, p = .003). Further, significant associations were observed between plasma Aß40 and the K/T (r = .375, p < .0005), kynurenine (r = .374, p < .0005), kynurenic acid (r = .352, p < .0005), anthranilic acid (r = .381, p < .0005), and quinolinic acid (r = .352, p < .0005). Significant associations were also observed between plasma Aß42 and the K/T ratio (r = .215, p = .034), kynurenic acid (r = .214, p = .035), anthranilic acid (r = .278, p = .006), and quinolinic acid (r = .224, p = .027) in the cohort. On stratifying participants based on their neocortical Aß load (NAL) status, NFL correlated with KP metabolites irrespective of NAL status; however, associations between plasma Aß and KP metabolites were only pronounced in individuals with high NAL while associations in individuals with low NAL were nearly absent. CONCLUSIONS: The current study shows that KP metabolite changes are associated with biomarker evidence of neurodegeneration. Additionally, the association between KP metabolites and plasma Aß seems to be NAL status dependent. Finally, the current study suggests that an association between neurodegeneration and neuroinflammation manifests in the periphery, suggesting that preventing cytoskeleton cytotoxicity by KP metabolites may have therapeutic potential.
Assuntos
Doença de Alzheimer/sangue , Peptídeos beta-Amiloides/sangue , Biomarcadores/sangue , Cinurenina/metabolismo , Proteínas de Neurofilamentos/sangue , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , MasculinoRESUMO
Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in blood samples, and has been associated with Alzheimer's disease (AD). However, plasma GFAP has not been investigated in cognitively normal older adults at risk of AD, based on brain amyloid-ß (Aß) load. Cross-sectional analyses were carried out for plasma GFAP and plasma Aß1-42/Aß1-40 ratio, a blood-based marker associated with brain Aß load, in participants (65-90 years) categorised into low (Aß-, n = 63) and high (Aß+, n = 33) brain Aß load groups via Aß positron emission tomography. Plasma GFAP, Aß1-42, and Aß1-40 were measured using the Single molecule array (Simoa) platform. Plasma GFAP levels were significantly higher (p < 0.00001), and plasma Aß1-42/Aß1-40 ratios were significantly lower (p < 0.005), in Aß+ participants compared to Aß- participants, adjusted for covariates age, sex, and apolipoprotein E-ε4 carriage. A receiver operating characteristic curve based on a logistic regression of the same covariates, the base model, distinguished Aß+ from Aß- (area under the curve, AUC = 0.78), but was outperformed when plasma GFAP was added to the base model (AUC = 0.91) and further improved with plasma Aß1-42/Aß1-40 ratio (AUC = 0.92). The current findings demonstrate that plasma GFAP levels are elevated in cognitively normal older adults at risk of AD. These observations suggest that astrocytic damage or activation begins from the pre-symptomatic stage of AD and is associated with brain Aß load. Observations from the present study highlight the potential of plasma GFAP to contribute to a diagnostic blood biomarker panel (along with plasma Aß1-42/Aß1-40 ratios) for cognitively normal older adults at risk of AD.
Assuntos
Doença de Alzheimer , Idoso , Peptídeos beta-Amiloides , Apolipoproteína E4 , Estudos Transversais , Proteína Glial Fibrilar Ácida , Humanos , Fragmentos de PeptídeosRESUMO
The present study examined the effects of waterborne cadmium (Cd) exposure on ionic balance and ionocyte density in developing zebrafish (Danio rerio) (0-4 days post-fertilization). Fish exposed to 1 or 10 µg Cd/L exhibited an increase in whole body Cd level. Exposure to 10 µg Cd/L also significantly reduced whole body content of Ca2+, but not other major ions (e.g., Na+, K+ and Mg2+). Such reduction was accompanied by a decrease in the density of Ca2+-transporting ionocytes, the Na+/K+-ATPase-rich cells (NaRCs). However, the densities of other ionocyte subtypes (e.g., Na+-transporting ionocytes) remained unchanged after exposure to 10 µg Cd/L. The potential interactive effects between water chemistry and Cd exposure on ionocyte density were examined further in Cd-exposed larvae acclimated to different water NaCl or Ca2+ levels. The results demonstrated that NaRC density increased in fish acclimated to low Ca2+ water, presumably increasing Ca2+ uptake for maintaining Ca2+ homeostasis. However, Cd exposure completely abolished the increased NaRC density in low water Ca2+ environments. The increased NaRCs over development was also reduced in Cd-exposed larvae. In conclusion, our study suggested that Cd exposure reduces the density of NaRCs and suppresses the compensatory regulation of NaRCs during acclimation to low water Ca2+ level. These inhibitory effects by Cd exposure ultimately disrupt Ca2+ balance in the early life stages of zebrafish.
Assuntos
Cádmio/toxicidade , Poluentes Químicos da Água/toxicidade , Peixe-Zebra/fisiologia , Animais , Transporte Biológico , Homeostase , Íons , Larva/metabolismo , ATPase Trocadora de Sódio-Potássio/metabolismo , Peixe-Zebra/metabolismo , Proteínas de Peixe-Zebra/metabolismoRESUMO
BACKGROUND/OBJECTIVE: Hepcidin, an iron-regulating hormone, suppresses the release of iron by binding to the iron exporter protein, ferroportin, resulting in intracellular iron accumulation. Given that iron dyshomeostasis has been observed in Alzheimer's disease (AD) together with elevated serum hepcidin levels, the current study examined whether elevated serum hepcidin levels are an early event in AD pathogenesis by measuring the hormone in cognitively normal older adults at risk of AD, based on high neocortical amyloid-ß load (NAL). METHODS: Serum hepcidin levels in cognitively normal participants (nâ=â100) aged between 65-90 years were measured using ELISA. To evaluate NAL, all participants underwent 18F-florbetaben positron emission tomography. A standard uptake value ratio (SUVR)<1.35 was classified as low NAL (nâ=â65) and ≥1.35 (nâ=â35) was classified as high NAL. RESULTS: Serum hepcidin was significantly higher in participants with high NAL compared to those with low NAL before and after adjusting for covariates: age, gender, and APOEÉ4 carriage (pâ<â0.05). A receiver operating characteristic curve based on a logistic regression of the same covariates, the base model, distinguished high from low NAL (area under the curve, AUCâ=â0.766), but was outperformed when serum hepcidin was added to the base model (AUCâ=â0.794) and further improved with plasma Aß42/40 ratio (AUCâ=â0.829). CONCLUSION: The present findings indicate that serum hepcidin is increased in individuals at risk for AD and contribute to the body of evidence supporting iron dyshomeostasis as an early event of AD. Further, hepcidin may add value to a panel of markers that contribute toward identifying individuals at risk of AD; however, further validation studies are required.
Assuntos
Peptídeos beta-Amiloides/sangue , Cognição/fisiologia , Hepcidinas/sangue , Neocórtex/metabolismo , Fragmentos de Peptídeos/sangue , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Biomarcadores/metabolismo , Estudos Transversais , Feminino , Humanos , Masculino , Tomografia por Emissão de Pósitrons/métodosRESUMO
BACKGROUND: Aberrant amyloid-ß (Aß) deposition in the brain occurs two decades prior to the manifestation of Alzheimer's disease (AD) clinical symptoms and therefore brain Aß load measured using PET serves as a gold standard biomarker for the early diagnosis of AD. However, the uneconomical nature of PET makes blood markers, that reflect brain Aß deposition, attractive candidates for investigation as surrogate markers. OBJECTIVE: Investigation of plasma Aß as a surrogate marker for brain Aß deposition in cognitively normal elderly individuals. METHODS: Plasma Aß40 and Aß42 concentrations were measured using the ultrasensitive Single Molecule Array (Simoa) assay in 95 cognitively normal elderly individuals, who have all undergone PET to assess brain Aß deposition. Based on the standard uptake value ratios (SUVR) obtained from PET imaging, using the tracer 18F-Florbetaben, plasma Aß was compared between 32 participants assessed to have low brain Aß load (Aß-, SUVR <1.35) and 63 assessed to have high brain Aß load (Aß+, SUVR ≥1.35). RESULTS: Plasma Aß42/Aß40 ratios were lower in the Aß+ group compared to the Aß-group. Plasma Aß40 and Aß42 levels were not significantly different between Aß-and Aß+ groups, although a trend of higher plasma Aß40 was observed in the Aß+ group. Additionally, plasma Aß42/Aß40 ratios along with the known AD risk factors, age and APOEÉ4 status, resulted in Aß+ participants being distinguished from Aß-participants based on an area under the receiver operating characteristic curve shown to be 78%. CONCLUSION: Plasma Aß ratios in this study are a potential biomarker for brain Aß deposition and therefore, for preclinical AD. However, this method to measure plasma Aß needs further development to increase the accuracy of this promising AD blood biomarker.
Assuntos
Doença de Alzheimer/sangue , Doença de Alzheimer/psicologia , Peptídeos beta-Amiloides/sangue , Biomarcadores/sangue , Cognição , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/diagnóstico por imagem , Apolipoproteínas E/sangue , Apolipoproteínas E/genética , Feminino , Humanos , Masculino , Testes Neuropsicológicos , Fragmentos de Peptídeos/sangue , Tomografia por Emissão de Pósitrons , RiscoRESUMO
BACKGROUND: The disruption of neurofilament, an axonal cytoskeletal protein, in neurodegenerative conditions may result in neuronal damage and its release into the cerebrospinal fluid and blood. In Alzheimer's disease (AD), neurofilament light chain (NFL), a neurofilament subunit, is elevated in the cerebrospinal fluid and blood. OBJECTIVE: Investigate the association of plasma NFL with preclinical-AD features, such as high neocortical amyloid-ß load (NAL) and subjective memory complaints, and cognitive performance in cognitively normal older adults. METHODS: Plasma NFL concentrations were measured employing the single molecule array platform in participants from the Kerr Anglican Retirement Village Initiative in Ageing Health cohort, aged 65- 90 years. Participants underwent a battery of neuropsychological testing to evaluate cognitive performance and were categorized as low NAL (NAL-, nâ=â65) and high NAL (NAL+, nâ=â35) assessed via PET, and further stratified into subjective memory complainers (SMC; nNAL-â=â51, nNAL+â=â25) and non-SMC (nNAL-â=â14, nNAL+â=â10) based on the Memory Assessment Clinic- Questionnaire. RESULTS: Plasma NFL inversely correlated with cognitive performance. No significant difference in NFL was observed between NAL+ and NAL- participants; however, within APOEÉ4 non-carriers, higher NAL was observed in individuals with NFL concentrations within quartiles 3 and 4 (versus quartile 1). Additionally, within the NAL+ participants, SMC had a trend of higher NFL compared to non-SMC. CONCLUSION: Plasma NFL is inversely associated with cognitive performance in elderly individuals. While plasma NFL may not reflect NAL in individuals with normal global cognition, the current observations indicate that onset of axonal injury, reflected by increased plasma NFL, within the preclinical phase of AD may contribute to the pathogenesis of AD.
Assuntos
Envelhecimento/metabolismo , Peptídeos beta-Amiloides/metabolismo , Neocórtex/metabolismo , Proteínas de Neurofilamentos/sangue , Idoso , Idoso de 80 Anos ou mais , Envelhecimento/genética , Envelhecimento/psicologia , Apolipoproteínas E/genética , Biomarcadores/metabolismo , Estudos de Coortes , Feminino , Humanos , Masculino , Testes NeuropsicológicosRESUMO
The kynurenine pathway (KP) is dysregulated in neuroinflammatory diseases including Alzheimer's disease (AD), however has not been investigated in preclinical AD characterized by high neocortical amyloid-ß load (NAL), prior to cognitive impairment. Serum KP metabolites were measured in the cognitively normal KARVIAH cohort. Participants, aged 65-90 y, were categorised into NAL+ (n = 35) and NAL- (n = 65) using a standard uptake value ratio cut-off = 1.35. Employing linear models adjusting for age and APOEε4, higher kynurenine and anthranilic acid (AA) in NAL+ versus NAL- participants were observed in females (kynurenine, p = 0.004; AA, p = 0.001) but not males (NALxGender, p = 0.001, 0.038, respectively). To evaluate the predictive potential of kynurenine or/and AA for NAL+ in females, logistic regressions with NAL+/- as outcome were carried out. After age and APOEε4 adjustment, kynurenine and AA were individually and jointly significant predictors (p = 0.007, 0.005, 0.0004, respectively). Areas under the receiver operating characteristic curves were 0.794 using age and APOEε4 as predictors, and 0.844, 0.866 and 0.871 when kynurenine, AA and both were added. Findings from the current study exhibit increased KP activation in NAL+ females and highlight the predictive potential of KP metabolites, AA and kynurenine, for NAL+. Additionally, the current study also provides insight into he influence of gender in AD pathogenesis.
Assuntos
Doença de Alzheimer/diagnóstico , Peptídeos beta-Amiloides/metabolismo , Biomarcadores/sangue , Cinurenina/metabolismo , Neocórtex/metabolismo , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Doenças Assintomáticas , Biomarcadores/análise , Biomarcadores/metabolismo , Estudos de Casos e Controles , Estudos de Coortes , Progressão da Doença , Diagnóstico Precoce , Feminino , Humanos , Cinurenina/sangue , Masculino , Redes e Vias Metabólicas , Neocórtex/patologia , Projetos Piloto , Valor Preditivo dos Testes , Agregados ProteicosRESUMO
Brain and blood fatty acids (FA) are altered in Alzheimer's disease and cognitively impaired individuals, however, FA alterations in the preclinical phase, prior to cognitive impairment have not been investigated previously. The current study therefore evaluated erythrocyte FA in cognitively normal elderly participants aged 65-90 years via trans-methylation followed by gas chromatography. The neocortical beta-amyloid load (NAL) measured via positron emission tomography (PET) using ligand 18F-Florbetaben, was employed to categorise participants as low NAL (standard uptake value ratio; SUVR < 1.35, N = 65) and high NAL or preclinical AD (SUVR ≥ 1.35, N = 35) wherein, linear models were employed to compare FA compositions between the two groups. Increased arachidonic acid (AA, p < 0.05) and decreased docosapentaenoic acid (DPA, p < 0.05) were observed in high NAL. To differentiate low from high NAL, the area under the curve (AUC) generated from a 'base model' comprising age, gender, APOEε4 and education (AUC = 0.794) was outperformed by base model + AA:DPA (AUC = 0.836). Our findings suggest that specific alterations in erythrocyte FA composition occur very early in the disease pathogenic trajectory, prior to cognitive impairment. As erythrocyte FA levels are reflective of tissue FA, these alterations may provide insight into the pathogenic mechanism(s) of the disease and may highlight potential early diagnostic markers and therapeutic targets.